Sun Pharmaceuticals Industries Limited
Registry sponsor category
Industry
- Other names
- Sun Pharmaceuticals Industries Limited
- Company name
- Sun Pharmaceuticals Industries Limited
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (30)
- A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
- A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne
- A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
- A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
- A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
- A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
- A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients
- An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
- An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
- Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects
- Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
- Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
- Efficacy and Safety Study of SUNPG1622
- Efficacy and Safety Study of SUNPG1623
- Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
- Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
- ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.